Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...

The FDA warned against unapproved sunscreen forms, while Australian tests exposed inaccurate SPF claims, causing consumer ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Each Sunday we feature a highlight reel of various articles posted on our website that week.

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...

However, one significant problem has proven surprisingly durable: misdiagnosis of Type 1 diabetes (T1D). Estimates suggest ...

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...

Type 1 diabetes is a disease where the immune system destroys insulin-producing beta cells in pancreatic islets. About 2 million Americans have Type 1 diabetes. The islets of Langerhans are named for ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...

Independent practices face challenges from consolidation and policy shifts, with hybrid models offering autonomy while sharing financial risk. Value-based care in oncology prioritizes science, ...